ETELCALCETIDE bulk active fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
DC Chemicals	⤷ Start Trial	DC8189	⤷ Start Trial
Chemenu Inc.	⤷ Start Trial	CM100712	⤷ Start Trial
MuseChem	⤷ Start Trial	I006723	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

Etelcalcetide, marketed as Parsabiv®, is a novel calcimimetic agent used for managing secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. As a peptide-based drug, etelcalcetide’s manufacturing process hinges on sourcing high-quality APIs that comply with stringent regulatory standards. With the growing global demand for peptide APIs, the choice of API suppliers significantly impacts the supply chain, drug pricing, and regulatory compliance.

This article provides a comprehensive overview of the primary sources of bulk etelcalcetide API, evaluating their manufacturing capabilities, regulatory status, quality assurance processes, and strategic considerations for pharmaceutical companies seeking reliable API supply.

Overview of Etelcalcetide API

Etelcalcetide is a synthetic peptide comprising approximately 45 amino acids, designed to mimic calcium-sensing receptor modulators. Its manufacturing involves complex peptide synthesis processes, including solid-phase peptide synthesis (SPPS), purification, and stabilization techniques to ensure bioactivity and stability.

Given its peptide nature, sourcing bulk API requires suppliers possessing advanced peptide synthesis infrastructure, robust quality management systems, and a deep understanding of peptide chemistry regulations (e.g., ICH Q7a guidelines).

Major API Suppliers for Etelcalcetide

1. Pharmaceutical Contract Manufacturing Organizations (CMOs) Specializing in Peptide APIs

Several CMOs with global reach have established expertise in peptide synthesis and peptide API manufacturing, serving as prominent sources for etelcalcetide API.

a. Polypeptides Group (France)

Capabilities: Polypeptides specializes in custom peptide synthesis, including therapeutic peptides, with ISO 9001 and cGMP certifications.
API Production: Their facilities support complex peptide synthesis, peptide modification, and lyophilization, providing high-purity APIs suitable for clinical and commercial products.
Strengths: Proven track record in regulatory compliance and quality assurance, leveraging advanced peptide manufacturing technology.

b. GenScript ProBio (China)

Capabilities: A leading global biotech CDMO offering custom peptide synthesis up to multi-gram and kilogram scale, with extensive GMP-compliant facilities.
API Production: Capable of manufacturing peptides with specific modifications and high purity, adhering to international regulatory standards.
Strengths: Cost-effective manufacturing, rapid scaling, and comprehensive analytical support.

c. Bachem (Switzerland & USA)

Capabilities: Bachem supplies peptides from research to large-scale production, employing proprietary chemistries to ensure high purity.
API Production: Their facilities adhere to cGMP standards, with extensive experience in peptide pharmaceuticals.
Strengths: High product quality, stringent quality controls, and global regulatory approvals.

2. Large-Scale Peptide API Manufacturers with Emerging Capabilities

Some larger pharmaceutical manufacturers have in-house peptide synthesis units for proprietary APIs and may offer custom peptide APIs, including etelcalcetide.

a. WuXi Biologics (China)

Capabilities: Extensive biologics and peptide API manufacturing infrastructure, including peptide synthesis, conjugation, and purification.
API Production: Capable of scaling up peptide APIs with high stringent quality and regulatory compliance.
Strengths: Integration with biologics development pipelines, competitive pricing, and global regulatory presence.

b. Novartis (Switzerland)

Capabilities: As a pioneer in peptide drug development, Novartis has in-house capabilities for peptide synthesis and API manufacturing.
Potential Role: Likely to manufacture etelcalcetide through internal or partner facilities for commercial supply.

Emerging and Niche API Suppliers

Certain specialized peptide synthesis firms focus on niche or orphan peptides, including APIs with complex modifications.

a. CJ CheilJedang (South Korea)

Capabilities: Known for peptide development and manufacturing, particularly in the Asia-Pacific region.
API Capabilities: Capable of producing high-purity peptide APIs, compliant with cGMP standards.

b. Aimovant (India)

Capabilities: Focuses on peptide synthesis and custom APIs, leveraging cost advantages and scaling expertise.

Strategic Considerations in API Sourcing

Regulatory Compliance: Ensuring suppliers adhere to GMP standards and possess relevant certifications (e.g., FDA, EMA, PMDA) is vital to avoid regulatory delays.
Quality Assurance: Suppliers must demonstrate consistent batch-to-batch quality, comprehensive analytical validation, and stability data.
Manufacturing Capacity: The complexity of peptide synthesis necessitates suppliers capable of scaling production to meet demand fluctuations.
Intellectual Property (IP): Due diligence on existing patents and licensing agreements is crucial to avoid infringement issues.
Supply Chain Security: Geographic diversification of suppliers mitigates risks associated with geopolitical disruptions, natural disasters, or pandemics.

Challenges in Sourcing Etelcalcetide API

Complex Manufacturing Processes: Peptide synthesis's intricacy demands specialized facilities and process validation, increasing production costs and lead times.
Regulatory Stringency: Stringent regulation of peptide APIs necessitates comprehensive documentation, stability data, and process controls.
Limited Number of Specialists: The niche nature of peptide API manufacturing reduces supplier options, emphasizing the need for strategic partnerships.

Future Outlook

With ongoing innovation in peptide synthesis, including solid-phase synthesis advances and automation, the supply landscape for etelcalcetide API is anticipated to expand. Increased capacity at established peptide CMOs and rising interest from biotech firms may enhance global supply resilience.

The trend toward regional manufacturing facilities, especially in Asia, promises to reduce costs and lead times, facilitating wider access to high-quality etelcalcetide APIs.

Key Takeaways

Dedicated peptide CMOs such as Polypeptides, Bachem, and GenScript are leading suppliers for etelcalcetide API, offering high-quality, GMP-compliant products suitable for commercial manufacturing.
Regulatory compliance, consistent quality, and manufacturing capacity are critical considerations in selecting an API supplier.
Supply chain resilience can be enhanced through geographic diversification of suppliers and establishing strategic partnerships with established peptide manufacturers.
Emerging manufacturers in Asia and South Korea provide cost-effective alternatives, but thorough quality and regulatory assessments are vital.
Ongoing technological advances in peptide synthesis are likely to expand the pool of reliable API sources, reducing costs and improving supply chain security.

FAQs

1. What are the primary challenges in sourcing etelcalcetide API?
The main challenges include complex peptide synthesis processes requiring specialized facilities, stringent regulatory standards, maintaining consistent quality, and managing manufacturing lead times and costs.

2. Which regions are most prominent in peptide API manufacturing for etelcalcetide?
Europe and North America house leading providers like Bachem and Polypeptides. Asia-Pacific, notably China and South Korea, increasingly offers cost-effective and scalable peptide manufacturing capabilities.

3. How does regulatory compliance influence API sourcing?
Regulatory standards such as cGMP certification, validated manufacturing processes, and comprehensive analytical documentation ensure the APIs meet safety, quality, and efficacy criteria essential for regulatory approval.

4. Can smaller biotech firms source etelcalcetide API directly from contractors?
Yes, but they must assess supplier capacity, regulatory compliance, and quality assurance processes. Partnerships with established CMOs significantly mitigate risks and streamline regulatory pathways.

5. What trends are shaping the future of peptide API supply chains?
Automation, process innovations, regional manufacturing hubs, and increased collaboration with CMOs are expanding capacity, reducing costs, and bolstering supply resilience for peptide APIs like etelcalcetide.

References

Patel, D., & Sharma, A. (2022). Peptide API Manufacturing: Challenges and Opportunities. Journal of Pharmaceutical Innovation.
International Council for Harmonisation (ICH). Q7a Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
Bachem. (2023). Peptide Capabilities & Manufacturing. [Website]
Polypeptides Group. (2023). Custom Peptide Synthesis and API Production. [Website]
GenScript ProBio. (2023). Peptide Product Portfolio. [Website]

Bulk Pharmaceutical API Sources for ETELCALCETIDE